DLL3, expressed in most SCLC patients, is a critical therapeutic target driven by the transcription factor ASCL1, enhancing tumorigenic, clonogenic, and metastatic capacities in preclinical models (27, 53, 108, 129, 130). The gene discussed is ASCL1; the disease is small cell lung carcinoma.